Cargando…
[(18)F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial
INTRODUCTION: The oligometastatic (OM) disease hypothesis of an intermediate metastatic state with limited distant disease deposits amenable for curative therapies remains debatable. Over a third of prostate cancer (PCa) patients treated with radical prostatectomy and postoperative radiotherapy expe...
Autores principales: | Glicksman, Rachel M, Metser, Ur, Valliant, John, Chung, Peter W, Fleshner, Neil E, Bristow, Robert G, Green, David, Finelli, Antonio, Hamilton, Robert, Stanescu, Teodor, Hussey, Douglas, Catton, Charles, Gospodarowicz, Mary, Warde, Padraig, Bayley, Andrew, Breen, Stephen, Vines, Doug, Jaffray, David A, Berlin, Alejando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204865/ https://www.ncbi.nlm.nih.gov/pubmed/32327479 http://dx.doi.org/10.1136/bmjopen-2019-035959 |
Ejemplares similares
-
(18)F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center
por: Metser, Ur, et al.
Publicado: (2021) -
(18)F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study
por: Metser, Ur, et al.
Publicado: (2022) -
Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models
por: Bouvet, Vincent, et al.
Publicado: (2016) -
Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of (18)F-DCFPyL PET/CT Restaging
por: Liu, Wei, et al.
Publicado: (2020) -
Competitive blocking of salivary gland [(18)F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study
por: Roy, Jyoti, et al.
Publicado: (2021)